

DE LEESTAFEL

FEBRUARI 2020

*Een Maandelijks Selectie van Wetenschappelijke GE-
nieuws*

Coloproctologie

Robot chirurgie? Of toch laparoscopie?

Perioperative Outcomes and Trends in the Use of Robotic Colectomy for Medicare Beneficiaries From 2010 Through 2016. KH Sheetz et al. *JAMA Surg.* 2020;155(1):41-49.

Pubmed ID: 31617874.

Importance: The use of robotic surgery for common operations like colectomy is increasing rapidly in the United States, but evidence for its effectiveness is limited and may not reflect real-world practice.

Objective: To evaluate outcomes of and trends in the use of robotic, laparoscopic, and open colectomy across diverse practice settings.


Design, Setting, and Participants: This population-based study of Medicare beneficiaries undergoing elective colectomy was conducted between January 2010 and December 2016. We used an instrumental variable analysis to account for both measured and unmeasured differences in patient characteristics between robotic, open, and laparoscopic colectomy procedures. Data were analyzed from January 21, 2019, to March 1, 2019.

Exposures: Receipt of robotic colectomy.

Main Outcomes and Measures: Incidence of postoperative medical and surgical complications and length of stay.

Results: A total of 191 292 procedures (23 022 robotic procedures [12.0%], 87 639 open procedures [45.8%], and 80 631 laparoscopic colectomy procedures [42.0%]) were included. Robotic colectomy was associated with a lower adjusted rate of overall complications than open colectomy (17.6% [95% CI, 16.9%-18.2%] vs 18.6% [95% CI, 18.4%-18.7%]; relative risk [RR], 0.94 [95% CI, 0.91-0.98]). This difference was driven by lower rates of medical complications (15.5% [95% CI, 14.8%-16.2%] vs 16.9% [95% CI, 16.7%-17.1%]; RR, 0.92 [95% CI, 0.87-0.96]) because surgical complications were higher with the robotic approach (3.0% [95% CI, 2.8%-3.2%] vs 2.4% [95% CI, 2.3%-2.5%]; RR, 1.18 [95% CI, 1.04-1.35]). There were no differences in complications between robotic and laparoscopic colectomy (11.1% [95% CI, 10.5%-11.6%] vs 11.0% [95% CI, 10.8%-11.2%]; RR, 1.00 [95% CI, 0.95-1.05]). There was an overall shift toward greater proportional use of robotic colectomy from 0.7% (457 of 65 332 patients) in 2010 to 10.9% (8274 of 75 909 patients) in 2016. In hospitals with the highest adoption of robotic colectomy between 2010 and 2016, increasing use of robotic colectomy (0.8% [100 of 12 522 patients] to 32.8% [5416 of 16 511 patients]) was associated with a greater replacement of laparoscopic operations (43.8% [5485 of 12 522 patients] to 25.2% [4161 of 16 511 patients]) than open operations (55.4% [6937 of 12 522 patients] to 41.9% [6918 of 16 511 patients]).

Figure 1. Forest Plots Indicating the Relative Risk of Complications Associated With Robotic Colectomy Compared With Open or Laparoscopic Surgery



Conclusions and Relevance: While robotic colectomy was associated with minimal safety benefit over open colectomy and had comparable outcomes with laparoscopic colectomy, population-based trends suggest that it replaced a greater proportion of laparoscopic rather than open colectomy, especially in hospitals with the highest adoption of robotics.

Nationale Zweedse studie met focus op jonge colorectal carcinoom patiënten

Population - based analysis of outcomes with early - age colorectal cancer. D Saraste et al. *BJs*, Feb 2020 – Volume 107 – Issue 3, pages 301-309.
 Pubmed ID: 31925793.


BACKGROUND: The aim was to evaluate differences in stage, treatment and prognosis in patients aged less than 50 years with colorectal cancer compared with older age groups.

METHODS: This population-based study included all patients diagnosed with colorectal cancer in Sweden, 2010-2015. Disease stage, treatment, 5-year disease-free survival (DFS) and relative survival were analysed in relation to age groups: less than 50, 50-74 and at least 75 years.

RESULTS: Of 34 434 patients included, 24.1, 19.7 and 14.0 per cent of patients aged less than 50, 50-74 and at least 75 years respectively were diagnosed with stage IV disease ($P < 0.001$). Adverse histopathological features were more common in young patients. Among patients aged less than 50 years, adjuvant chemotherapy was given to 18.9, 42.0 and 93.9 per cent of those with stage I, III and III disease respectively, compared with 0.7, 4.4 and 29.6 per cent of those aged 75 years or older ($P < 0.001$). Stage-adjusted DFS at 5 years for patients under 50 years old was 0.96, 0.90 and 0.77 in stage I, II and III respectively. Corresponding proportions were 0.88, 0.82 and 0.68 among patients aged 50-74 years, and 0.69, 0.62 and 0.49 for those aged 75 years or older. Relative survival was better for young patients only among those with stage III disease.

CONCLUSION: Patients younger than 50 years with colorectal cancer had a poorer stage at diagnosis and received more intensive oncological treatment. DFS was better than that among older patients in early-stage disease.

Fig. 1 Disease-free and 5-year relative survival after elective surgery in patients with pTNM stage I–III colorectal cancer



Disease-free survival (DFS): a stage I, b stage II and c stage III; relative survival: d stage I, e stage II and f stage III. a $P < 0.001$, b $P < 0.001$, c $P < 0.001$ (log rank test); a $P = 0.108$, b $P = 0.356$, c $P < 0.001$ (likelihood ratio test).

UPPER GI

Langdurig effect van postoperatieve complicaties na oesophagus carcinoom chirurgie

Postoperative Complications and Health-related Quality of Life 10 Years After Esophageal Cancer Surgery. JH Kauppila et al. *Annals of Surgery*, February 2020 - Volume 271 - Issue 2 p. 311-316.
Pubmed ID: 29995688.

OBJECTIVE: To evaluate the impact of postoperative complications on health-related quality of life (HRQOL) up to 10 years after surgery for esophageal cancer.

BACKGROUND: The impact of postoperative complications on HRQOL past 5 years is unknown.

METHODS: Some 616 patients undergoing open esophageal cancer surgery between April 2, 2001 and December 31, 2005 in Sweden were enrolled in this population-based, nationwide, and prospective cohort study. Exposure was the occurrence of predefined postoperative complications, and the outcome was HRQOL evaluated by validated European Organization for Research and Treatment of Cancer questionnaires at 6 months, 3, 5, and 10 years after surgery. Linear mixed models, adjusted for longitudinal HRQOL in the general population and confounders, provided mean score differences (MDs) with 95% confidence intervals (CIs) for each HRQOL item and scale in patients with or without postoperative complications.

RESULTS: At 10 years, 104 (17%) patients were alive and 92 (88%) answered the HRQOL questionnaires. Of these, 37 (40%) had at least 1 predefined postoperative complication. Twelve of the 25 scales and items were significantly worse in patients with postoperative complications 10 years after surgery, for example, physical function (MD -15, 95% CI -24 to -7), fatigue (MD 16, 95% CI 5-26), pain (MD 18, 95% CI 7-30), dyspnea (MD 15, 95% CI 2-27), insomnia (MD 20, 95% CI 8-32), and eating problems (MD 14, 95% CI 3-24) compared to patients without complications.

CONCLUSIONS: Postoperative complications are associated with considerably impaired HRQOL up to 10 years after esophageal cancer surgery.

Wat is de aangewezen modaliteit voor response bepaling na neoadjuvante chemoradiotherapie voor oesophagus carcinoom?

Accuracy of Detecting Residual Disease After Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Systematic Review and Meta-analysis. BM Eyck et al. *Annals of Surgery*, February 2020 - Volume 271 - Issue 2 p. 245-25.
Pubmed ID: 31188203.

OBJECTIVE: The aim of this study was to perform a meta-analysis on the accuracy of endoscopic biopsies, EUS, and 18F-FDG PET(-CT) for detecting residual disease after neoadjuvant chemoradiotherapy (nCRT) for esophageal cancer.

SUMMARY OF BACKGROUND DATA: After nCRT, one-third of patients have a pathologically complete response in the resection specimen. Before an active surveillance strategy could be offered to these patients, clinically complete responders should be accurately identified.

METHODS: Embase, Medline, Cochrane, and Web-of-Science were searched until February 2018 for studies on accuracy of endoscopic biopsies, EUS, or PET(-CT) for detecting locoregional residual disease after nCRT for squamous cell- or adenocarcinoma. Pooled sensitivities and specificities were calculated using random-effect meta-analyses.

RESULTS: Forty-four studies were included for meta-analyses. For detecting residual disease at the primary tumor site, 12 studies evaluated endoscopic biopsies, 11 qualitative EUS, 14 qualitative PET, 8 quantitative PET using maximum standardized uptake value (SUVmax), and 7 quantitative PET using percentage reduction of SUVmax (% Δ SUVmax). Pooled sensitivities and specificities were 33% and 95% for endoscopic biopsies, 96% and 8% for qualitative EUS, 74% and 52% for qualitative PET, 69% and 72% for PET-SUVmax, and 73% and 63% for PET-% Δ SUVmax. For detecting residual nodal disease, 11 studies evaluated qualitative EUS with a pooled sensitivity and specificity of 68% and 57%, respectively. In subgroup analyses, sensitivity of PET-% Δ SUVmax and EUS for nodal disease was higher in squamous cell carcinoma than adenocarcinoma.

CONCLUSIONS: Current literature suggests insufficient accuracy of endoscopic biopsies, EUS, and 18F-FDG PET(-CT) as single modalities for detecting residual disease after nCRT for esophageal cancer.

Minimaal invasief vs open centrale pancreatectomie

An 8-year single-center study: 170 cases of middle pancreatotomy, including 110 cases of robot-assisted middle pancreatotomy. Y. Shi et al; Surgery: February 2020 – Volume 167 – Issue 2 – p 436-441.

Pubmed ID: 31629541.

BACKGROUND: The aim of this study was to determine the feasibility, safety, and rate of postoperative complications after robot-assisted middle pancreatotomy compared with open middle pancreatotomy.

METHODS: This retrospective study was conducted in Shanghai Ruijin Hospital, China, involving 170 patients who underwent robot-assisted middle pancreatotomy or open middle pancreatotomy from December 2010 to December 2017. Patients were in 1 of 2 groups: robot-assisted middle pancreatotomy (n = 110) and open middle pancreatotomy (n = 60).

RESULTS: Among the 110 patients who underwent robot-assisted middle pancreatotomy, age, operation time, blood loss, and tumor size were 47 ± 14 y, 162 ± 63 min, 88 ± 93 mL, and 2.4 ± 1.3 cm (mean \pm standard deviation), respectively. Among the 60 patients who underwent open middle pancreatotomy, age, operation time, blood loss, and tumor size were 53 ± 14 y, 208 ± 52 min, 195 ± 165 mL, and 2.5 ± 1.4 cm (mean \pm standard deviation), respectively. Mean operation time and blood loss were less in the robot-assisted middle pancreatotomy group ($P < .001$ each). Overall morbidity rate in the robot-assisted middle pancreatotomy group was 51.8% and 40% in open middle pancreatotomy group ($P = .140$). Clinically relevant postoperative pancreatic fistulas developed in 38 (34.5%) patients in the robot-assisted middle pancreatotomy group and 13 (22%) in the open middle pancreatotomy group ($P = .105$). A total of 10 patients in the robot-assisted middle pancreatotomy group and 3 patients in the open middle pancreatotomy group required a reoperation or angiographic embolization because of postoperative bleeding. The mean hospital stay was similar in the 2 groups (25 ± 13 d versus and 24 ± 18 d). There was 1 postoperative death in each group because of postoperative bleeding and a pulmonary embolus, respectively. The tumors in this study included 65 serous cystic neoplasms, 6 mucinous cystic neoplasms, 35 intraductal papillary mucinous neoplasms, 29 pancreatic neuroendocrine tumors, 31 solid pseudopapillary tumors, 1 paraganglioma, and 3 pancreatic cysts.

CONCLUSION: Middle pancreatotomy is a safe and effective robotic operative procedure, and when possible, robot-assisted middle pancreatotomy might be the preferred method, because it was associated with decreased operative time and decreased blood loss. The lesser operation time might be attributed to different reconstruction methods that were chosen in the open and robotic approach. Pancreatic fistula remains the major complication.

Table IV
Recent review of reports including more than 25 cases of MP

Authors	Year	Case number	Technique	Type of anastomosis		Overall morbidity (%)	CR-POPF rate(%)	30-d Mortality (%)
				PG (%)	PJ (%)			
DiNordia et al ²⁵	2010	73	Open	97	3	41	21	0
Cataldegirmen et al ¹⁵	2010	35	Open	0	100	26	14	0
Du et al ¹⁷	2013	36	Open	0	100	48	42	0
Song et al ¹⁸	2015	26	Laparoscopic	0	100	39	19	0
Dokmak et al ¹⁶	2017	35	Laparoscopic	100	0	74	51	0
Our study								
RMP	2019	110	Robotic	100	0	59.1	34.5	1.0
OMP	2019	60	Open	0	100	45	22	1.7

PG, pancreatogastronomy; PJ, pancreaticojejunostomy.

Verandering volume pancreaskop na pancreasstaartresectie

Volume changes of the pancreatic head remnant after distal pancreatectomy. F. Flupp et al. *Surgery*: February 2020 – Volume 167 – Issue 2 – p 455-467.

Pubmed ID: 31630778.

BACKGROUND: Little is known about pancreatic regeneration in humans after surgical resection. We examined pancreatic head volume changes after distal pancreatectomy.

METHODS: Using computed tomography or magnetic resonance imaging volumetry, we assessed volume changes of the pancreatic head remnant in 67 patients at defined time points (3, 6, 9, and 12 months) after distal pancreatectomy. A volume increase of $>1 \text{ cm}^3$ was defined as hypertrophy, a decrease of $>1 \text{ cm}^3$ as atrophy, and alterations of $\pm 1 \text{ cm}^3$ were considered as unchanged. Volumetry results were correlated with clinical patient data, histology, and immunohistochemistry for the pancreatic regeneration markers Pax4, Ghrelin, cholecystokinin receptor A, and cholecystokinin receptor B of the resection margin.

RESULTS: Of 67 patients, 33 patients (49%) exhibited a hypertrophy of the pancreatic head remnant with a median increase of 5.08 cm^3 , 26 patients (39%) showed an atrophy, and in 8 patients (12%) pancreatic volume remained unchanged. No correlation of preoperative, postoperative, and new-onset diabetes with hypertrophy or atrophy was found. In patients with ductal adenocarcinoma, hypertrophy occurred less frequently compared to patients with other pathologies (38% vs 63%; $P = .04$). In patients with ductal adenocarcinoma, hypertrophy was associated with significantly shorter survival. Patients with a postoperative hypertrophy that did not suffer from ductal adenocarcinoma displayed significantly less fibrosis at the resection margin compared to patients with a postoperative atrophy and pancreatic ductal adenocarcinoma patients. Immunohistochemical staining revealed no differential expression of the tested regeneration markers in hypertrophy versus atrophy.

CONCLUSION: This study demonstrates volume changes of the pancreatic head remnant after distal pancreatectomy. Clinical and functional significance and underlying molecular mechanisms in humans remain unclear.




Fig 4. Overall survival in the subgroup of patients suffering from a ductal adenocarcinoma of the pancreas. Overall survival was significantly shorter in patients exhibiting a postoperative hypertrophy compared to patients exhibiting a postoperative atrophy of the pancreatic head remnant ($P = .008$).

LEVERCHIRURGIE

Cholecystectomy bij idiopathische pancreatitis?

Recurrence of idiopathic acute pancreatitis after cholecystectomy: systematic review and meta-analysis. D.S. Umans et al; *BJS*, Feb 2020 – Volume 107 – Issue 3, pages 191-199.

Pubmed ID: 31875953.


BACKGROUND: Occult biliary disease has been suggested as a frequent underlying cause of idiopathic acute pancreatitis (IAP). Cholecystectomy has been proposed as a strategy to prevent recurrent IAP. The aim of this systematic review was to determine the efficacy of cholecystectomy in reducing the risk of recurrent IAP.

METHODS: PubMed, Embase and Cochrane Library databases were searched systematically for studies including patients with IAP treated by cholecystectomy, with data on recurrence of pancreatitis. Studies published before 1980 or including chronic pancreatitis and case reports were excluded. The primary outcome was recurrence rate. Quality was assessed using the Newcastle-Ottawa Scale. Meta-analyses were undertaken to calculate risk ratios using a random-effects model with the inverse-variance method.

RESULTS: Overall, ten studies were included, of which nine were used in pooled analyses. The study population consisted of 524 patients with 126 cholecystectomies. Of these 524 patients, 154 (29.4 (95 per cent c.i. 25.5 to 33.3) per cent) had recurrent disease. The recurrence rate was significantly lower after cholecystectomy than after conservative management (14 of 126 (11.1 per cent) versus 140 of 398 (35.2 per cent); risk ratio 0.44, 95 per cent c.i. 0.27 to 0.71). Even in patients in whom IAP was diagnosed after more extensive diagnostic testing, including endoscopic ultrasonography or magnetic resonance cholangiopancreatography, the recurrence rate appeared to be lower after cholecystectomy (4 of 36 (11 per cent) versus 42 of 108 (38.9 per cent); risk ratio 0.41, 0.16 to 1.07).

CONCLUSION: Cholecystectomy after an episode of IAP reduces the risk of recurrent pancreatitis. This implies that current diagnostics are insufficient to exclude a biliary cause.

Fig. 3 Pooled analysis of recurrence of pancreatitis in patients with 'presumed' idiopathic acute pancreatitis treated with cholecystectomy versus conservative management



Risk ratios are shown with 95 per cent confidence intervals. A random-effects inverse-variance model was used for meta-analysis.

Impact van levercirrose op uitkomsten na laparoscopische leverresecties in Frankrijk

Impact of cirrhosis in patients undergoing laparoscopic liver resection in a nationwide multicentre survey. C. Hobeika et al. *BJS*, Feb 2020 – Volume 107 – Issue 3, pages 268-277.

Pubmed ID: 31916594.


BACKGROUND: The aim was to analyse the impact of cirrhosis on short-term outcomes after laparoscopic liver resection (LLR) in a multicentre national cohort study.

METHODS: This retrospective study included all patients undergoing LLR in 27 centres between 2000 and 2017. Cirrhosis was defined as F4 fibrosis on pathological examination. Short-term outcomes of patients with and without liver cirrhosis were compared after propensity score matching by centre volume, demographic and tumour characteristics, and extent of resection.

RESULTS: Among 3150 patients included, LLR was performed in 774 patients with (24.6 per cent) and 2376 (75.4 per cent) without cirrhosis. Severe complication and mortality rates in patients with cirrhosis were 10.6 and 2.6 per cent respectively. Posthepatectomy liver failure (PHLF) developed in 3.6 per cent of patients with cirrhosis and was the major cause of death (11 of 20 patients). After matching, patients with cirrhosis tended to have higher rates of severe complications (odds ratio (OR) 1.74, 95 per cent c.i. 0.92 to 3.41; $P = 0.096$) and PHLF (OR 7.13, 0.91 to 323.10; $P = 0.068$) than those without cirrhosis. They also had a higher risk of death (OR 5.13, 1.08 to 48.61; $P = 0.039$). Rates of cardiorespiratory complications ($P = 0.338$), bile leakage ($P = 0.286$) and reoperation ($P = 0.352$) were similar in the two groups. Patients with cirrhosis had a longer hospital stay than those without (11 versus 8 days; $P = 0.018$). Centre expertise was an independent protective factor against PHLF in patients with cirrhosis (OR 0.33, 0.14 to 0.76; $P = 0.010$).

CONCLUSION: Underlying cirrhosis remains an independent risk factor for impaired outcomes in patients undergoing LLR, even in expert centres.

Fig. 1 Rates of severe complications and mortality in patients with and without cirrhosis according to centre expertise



a Severe complications and **b** mortality. * $P < 0.050$, † $P < 0.010$ (Pearson's χ^2 or Fisher's exact test).

BARIATRISCHE CHIRURGIE

Refluxziekte na gastric sleeve een groot probleem?

Does Sleeve Gastrectomy Expose the Distal Esophagus to Severe Reflux?: A Systematic Review and Meta-analysis. K.T.D. Yeung et al. *Annals of Surgery*, February 2020 - Volume 271 - Issue 2 p. 257-265.

Pubmed ID: 30921053.

OBJECTIVE: The aim of this study was to appraise the prevalence of gastroesophageal reflux disease (GERD), esophagitis, and Barrett's esophagus (BE) after sleeve gastrectomy (SG) through a systematic review and meta-analysis.

BACKGROUND: The precise prevalence of new-onset or worsening GERD after SG is controversial. Subsequent esophagitis and BE can be a serious unintended sequelae. Their postoperative prevalence remains unclear.

METHODS: A systematic literature search was performed to identify studies evaluating postoperative outcomes in primary SG for morbid obesity. The primary outcome was prevalence of GERD, esophagitis, and BE after SG. Meta-analysis was performed to calculate combined prevalence.

RESULTS: A total of 46 studies totaling 10,718 patients were included. Meta-analysis found that the increase of postoperative GERD after sleeve (POGAS) was 19% and de novo reflux was 23%. The long-term prevalence of esophagitis was 28% and BE was 8%. Four percent of all patients required conversion to RYGB for severe reflux.

CONCLUSIONS: The postoperative prevalence of GERD, esophagitis, and BE following SG is significant. Symptoms do not always correlate with the presence of pathology. As the surgical uptake of SG continues to

increase, there is a need to ensure that surgical decision-making and the consent process for this procedure consider these long-term complications while also ensuring their postoperative surveillance through endoscopic and physiological approaches. The long-term outcomes of this commonly performed bariatric procedure should be considered alongside its weight loss and metabolic effects.

TABLE 2. Summary of All Study Outcomes ($P < 0.0001$ for All Studies)

Outcome	All Studies	Long Term (≥ 24 mo)
Overall increase in reported reflux	19%	19%
De novo reflux	23%	20%
Esophagitis found	30%	28%
Barrett's esophagus	6%	8%
Postoperative hiatus hernia rate	41%	—
PPI use (postoperative)	38%	36%
Revision to RYGB for severe reflux	4%	4%
BMI change	-13.29 kg/m ²	-12.56 kg/m ²
EWL	62%	61%
Diabetic resolution	66%	66%
GERD 2018 Lyon Consensus criteria (borderline)	37%	—
GERD 2018 Lyon Consensus criteria (conclusive)	8%	—

Ontwikkeling barbarische chirurgie in de VS

Changes in Utilization of Bariatric Surgery in the United States From 1993 to 2016. G.M. Campos et al. *Annals of Surgery*, February 2020 - Volume 271 - Issue 2 p. 201-209.

Pubmed ID: 31425292.

OBJECTIVE: The aim of this study was to obtain estimates of changes in perioperative outcomes and utilization of bariatric surgery in the United States from 1993 to 2016.

BACKGROUND: Bariatric surgery has evolved over the past 2 decades. Nationally representative information on changes of perioperative outcomes and utilization of surgery in the growing eligible population (class III obesity or class II obesity with comorbidities) is lacking.

METHODS: Adults with obesity diagnosis who underwent primary bariatric surgery in the United States from 1993 to 2016 were identified in the National Inpatient Sample database. Estimates of the yearly number, types and cost of surgeries, patients' and hospital characteristics, complications and mortality

rates were obtained. Prevalence of obesity and comorbidities were obtained from the National Health and Nutrition Examination Survey and changes in utilization of surgery were estimated.

RESULTS: An estimated 1,903,273 patients underwent bariatric surgery in the United States between 1993 and 2016. Mean age was 43.9 years (79.9% women, 70.9% white race, 70.7% commercial insurance); these and other characteristics changed over time. Surgeries were exclusively open operations in 1993 (n = 8,631; gastric bypass and vertical banded gastroplasty, 49% each) and 98% laparoscopic (n = 162,969; 69.8% sleeve gastrectomy and 27.8% gastric bypass) in 2016. Complication and mortality rates peaked in 1998 (11.7% and 1%) and progressively decreased to 1.4% and 0.04% in 2016. Utilization increased from 0.07% in 1993 to 0.62% in 2004 and remained low at 0.5% in 2016.

CONCLUSIONS: Perioperative safety of bariatric surgery improved over the last quarter-century. Despite growth in number of surgeries, utilization has only marginally increased. Addressing barriers for utilization may allow for greater access to surgical therapy.




FIGURE 2. Number of inpatient primary bariatric surgery procedures and initial admission complication and mortality rates in the United States from 1993 to 2016.
